Igc pharma introduces mint-ad: proprietary ai platform to predict alzheimer's risk and accelerate early detection

- multimodal foundation model enables personalized cognitive forecasts and expands access to alzheimer's diagnostics - potomac, md / access newswire / july 10, 2025 / igc pharma, inc. (nyse american:igc) a clinical-stage biopharmaceutical company focused on alzheimer's disease, today announced the development of mint-ad, multimodal interpretable transformer for alzheimer's, the company's proprietary ai-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear. mint-ad leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
IGC Ratings Summary
IGC Quant Ranking